Camber Spine Launches SPIRA-P and SPIRA-T Implants for National Distribution

In August of 2021, the U.S. Food and Drug Administration Gave 510(k) Clearance for Both Products

Camber Spine a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.

News of the national launch comes on the heels of Camber’s announcement last month that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for both products, which are indicated for use in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2-S1.

Part of the SPIRA® product platform, the SPIRA-P Posterior Lumbar Spacer can be utilized to accommodate PLIF or TLIF procedures and features a patented open architecture design for optimal endplate load distribution. Plus, its uniquely designed surface allows for cell adhesion and bone cell proliferation while its interconnected porosity design mimics bone.

The SPIRA-T Oblique Posterior Lumbar Spacer features the same qualities, but is designed specifically to accommodate traditional or “insert and rotate” TLIF procedures. Uniquely, its shape is angled for a 25° oblique insertion technique to optimize lordosis.

As with all products within Camber’s SPIRA technology platform, SPIRA-P and SPIRA-T include strategically placed and optimal sized openings for graft packing. The SPIRA products are designed to decrease the risk of subsidence with optimized endplate distribution and provide good visibility for fusion. The devices’ bone-like surface design promotes “mechanical fusion” bone ingrowth for short term stability and optimized biomimetic scaffolding designed to encourage osteogenesis.

SPIRA-P and SPIRA-T will be among the products displayed at Camber’s booth (#2027) at the North American Spine Society (NASS) 36th Annual Meeting in Boston next week.

“We are very excited to deliver more innovation-based solutions and options to the surgical community with our national launch of SPIRA-P and SPIRA-T, the first SPIRA implants available for the TLIF market,” said Camber Co-Founder and CEO, Daniel Pontecorvo. “Providing structural stability following discectomy, the SPIRA Posterior Lumbar Spacers have different shapes and designs to accommodate a broader array of posterior and transforaminal approaches and techniques.”

Pontecorvo added that Camber will also be launching an articulating, arched TLIF SPIRA cage product in early 2022.

SPIRA implants are 3D printed. This specialized manufacturing technology allows Camber to create unique patented structures featuring open arched matrices and proprietary surfaces designed to enhance fusion and promote bone growth.

All of Camber Spine’s products are developed and manufactured in the United States.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version